ArticleAdvanced healthcare materials2026
Ultrasensitive Detection of Porcine Epidemic Diarrhea Virus Infections Using Multivalent DNA Nanostructure-Enabled Lateral Flow Assay.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in DNA nanostructures for pathogenic microorganisms.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Early, rapid on-site detection of viral pathogens in livestock is critical to prevent disease spread, minimize economic losses, and safeguard food security. However, most current diagnostics are limited to centralized laboratories or require specialized equipment such as electrochemical readers, with a few hours to multi-day turnaround times that hinder field deployment. Here, we introduce a DNA nanostructure-enabled lateral flow assay (LFA) for rapid, ultrasensitive detection of porcine epidemic diarrhea virus (PEDV) directly on farms. This assay employs net-shaped DNA nanostructures presenting PEDV-specific aptamers in a multivalent configuration, yielding ∼1000-fold greater binding avidity than free aptamers. The platform demonstrates the limit of detection (LOD) of ∼1.33 ng/mL for recombinant PEDV nucleocapsid protein and ∼278 viral copies per test in pig oral fluid samples, with results obtained within 10 min without requiring nucleic acid extraction or amplification. Validation with animal clinical samples (n = 102) from swine farms demonstrates an accuracy of 97.06%, sensitivity of 96.92%, and specificity of 97.30% (Ct ≤ 37.42), without cross-reactivity against other swine viruses. This work presents a robust and field-deployable diagnostic platform that combines the programmability of DNA nanotechnology with the operational simplicity of LFA. Beyond PEDV, the modular nature of the DNA-Net platform is readily adaptable for detecting other veterinary and zoonotic pathogens, advancing disease surveillance, and One Health diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.